Clinical trials: Hematologic Disease
Leukemia, Myeloid, Acute
Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
The purpose of this study is to characterize the safety and tolerability of JNJ-63709178 and identify the recommended Phase 2 dose(s) (RP2D) and schedule for JNJ-63709178 in Part 1 and to characterize the safety and tolerability…
- Trial name
- NCT02715011
- Testing
- JNJ-63709178
- Where
- 10 sites in United States, Spain
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
- Trial name
- NCT03652064
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 114 sites in United States, Brazil and 11 more
- Volunteers
- 395 people
- Sponsor
- Janssen Research & Development, LLC
Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)
Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects
The purpose of this study is to demonstrate the bioequivalence of the clinical tablet formulation (100 mg x 5) to the clinical capsule formulation (100 mg x 5) in healthy subjects under fed condition (Cohort 1) and to investigate…
- Trial name
- NCT01374139
- Testing
- Bosutinib
- Where
- Singapore
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Pfizer
Disseminated Intravascular Coagulation
Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis
The primary objective of the study is to explore the efficacy and safety of ATryn® (antithrombin alfa) for the treatment of disseminated intravascular coagulation (DIC) associated with severe sepsis, when administered by…
- Trial name
- NCT00506519
- Testing
- Antithrombin alfa (INN name), Control (Standard treatment)
- Volunteers
- 25 people
- Sponsor
- LEO Pharma
Multiple Myeloma
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma
- Trial name
- NCT05238311
- Testing
- Elranatamab
- Sponsor
- Pfizer
Polycythemia Vera
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone.
- Trial name
- NCT07722611
- Testing
- Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b
- Where
- 2 sites in United States, Israel
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Sickle Cell Disease
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
This is a randomized, double-blind, placebo-controlled study in sickle cell disease participants with a history of Vaso-occlusive Crises (VOCs).
- Trial name
- NCT05098028
- Testing
- Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bausch Health Americas, Inc.
Acute Lymphoblastic Leukemia
Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions
The objective of this study was to assess the bioequivalence of a potential generic 6-mercaptopurine 50 mg tablet formulation compared with GlaxoSmithKline Purinethol® (mercaptopurine) 50-mg scored tablets following a single 50…
- Trial name
- NCT00602134
- Testing
- 6-Mercaptopurine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Hodgkin Disease, Lymphoma, Non-Hodgkin
A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation
Phase 2 study, conducted in patients with Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or mantle cell lymphoma undergoing high-dose chemotherapy and autologous stem cell transplantation.
- Conditions
- Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
- Trial name
- NCT00275262
- Testing
- Leuprolide acetate depot (LAD) 11.25 mg 3 Month
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Abbott
Relapsed or Refractory Multiple Myeloma
A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).
- Trial name
- BENCH (NCT04939142)
- Testing
- SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone)
- Where
- 33 sites in China
- Volunteers
- 154 people
- Sponsor
- Antengene Corporation
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
- Trial name
- NCT00532675
- Testing
- LBH589, Lenalidomide
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- NCT01910012
- Testing
- ADI-PEG 20
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 43 people
- Sponsor
- Polaris Group
Anemia, Cancer
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
The purpose of this study is to examine the effectiveness of epoetin alfa in treating anemia in patients who have cancer or who no longer have any signs of the cancer, but remain anemic as a result of their treatment.
- Trial name
- NCT00083434
- Testing
- Epoetin alfa
- Where
- 6 sites in United States
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Myelodysplastic Syndromes
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
The purpose of this study is to understand real-world effectiveness of luspatercept treatment among erythropoiesis-stimulating agents -naïve patients with lower-risk- myelodysplastic syndromes in the United States
- Trial name
- NCT06851065
- Testing
- Luspatercept, Erythropoiesis-stimulating agents
- Where
- United States
- Volunteers
- 418 people
- Sponsor
- Bristol-Myers Squibb
Hematologic Malignancies
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
- Trial name
- NCT01476657
- Testing
- IPI-145 (duvelisib)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- SecuraBio
Multiple Myeloma
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
- Trial name
- CAMMA 2 (NCT05535244)
- Testing
- Cevostamab, Tocilizumab
- Where
- 27 sites in United States, Australia and 6 more
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Hemophilia B
Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B
In this study a modified virus called adeno-associated virus (AAV) will be used to transfer a normal gene for human clotting factor IX into patients with severe hemophilia B (AAV human Factor IX vector).
- Trial name
- NCT00076557
- Testing
- Adeno-Associated Viral with Human Factor IX
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Avigen
Paroxysmal Nocturnal Hemoglobinuria
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
This is a multicenter, single-arm, open-label study. Patients with Paroxysmal Nocturnal Hemoglobinuria who had previously received and completed the HRS-5965 study well included.
- Trial name
- NCT06238544
- Testing
- HRS-5965 tablets, HRS-5965 Capsules
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Acute Myeloid Leukemia, AML, Adult
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).
- Trial name
- NCT04755244
- Testing
- evorpacept, venetoclax, azacitidine
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- ALX Oncology Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.